Compare AMTB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | CTMX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 977.1M |
| IPO Year | 2018 | 2015 |
| Metric | AMTB | CTMX |
|---|---|---|
| Price | $22.53 | $3.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $23.67 | $12.10 |
| AVG Volume (30 Days) | 221.5K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $7.67 | $7.61 |
| P/E Ratio | $50.59 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.62 | $1.72 |
| 52 Week High | $24.38 | $8.21 |
| Indicator | AMTB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 28.14 |
| Support Level | $21.98 | $3.39 |
| Resistance Level | $22.75 | $3.91 |
| Average True Range (ATR) | 0.55 | 0.21 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 32.16 | 4.84 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.